474890-08-9Relevant articles and documents
Facile formation of N-acyl-oxazolidinone derivatives using acid fluorides
Schindler, Corinna S.,Forster, Patrik M.,Carreira, Erick M.
supporting information; scheme or table, p. 4102 - 4105 (2010/11/19)
A mild method is presented for the formation of N-acylated oxazolidinones that employs acid fluorides and mild bases, such as iPr 2NEt and NEt3. Optimized reaction conditions for two types of substrates have been developed utilizing either the oxazolidinone itself or the corresponding in situ generated O-silyloxazolidinones resulting in the formation of the desired N-acylated products in high yields of up to 98%.
Direct entry to peptidyl ketones via SmI2-mediated C-C bond formation with readily accessible N-peptidyl oxazolidinones
Mittag, Tina,Christensen, Kasper L.,Lindsay, Karl B.,Nielsen, Niels Christian,Skrydstrup, Troels
, p. 1088 - 1092 (2008/09/18)
(Chemical Equation Presented) In this work, a new method for the preparation of peptidyl ketones is presented employing a SmI2/H 2O-mediated coupling of N-peptidyl oxazolidinones with electron-deficient alkenes. The requisite peptide
Expanding the scope of the acyl-type radical addition reactions promoted by SmI2
Karaffa, Jakob,Lindsay, Karl B.,Skrydstrup, Troels
, p. 8219 - 8226 (2007/10/03)
N-Acyl oxazolidinones of simple carboxylic acids and amino acids were observed to undergo successful SmI2-promoted couplings with substituted acrylamides and acrylates, affording a variety of functionalized γ-ketoamides and -esters with yields
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
-
, (2008/06/13)
PCT No. PCT/IB95/00442 Sec. 371 Date Dec. 2, 1997 Sec. 102(e) Date Dec. 2, 1997 PCT Filed Jun. 6, 1995 PCT Pub. No. WO96/39384 PCT Pub. Date Dec. 12, 1996Compounds of Formula (1) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.